Cuba sets up pharmaceutical industry group

29 November 2012

Cuba has announced the setting up of BioCubaFarma, the Biotechnological and Pharmaceutical Industry Group, from the merger of scientific centers, with the aim of producing medicines, equipment and services for the population and for exports, reports ACN, the Cuban news agency.

The initiative comes after a decision by the Cuban Council of State, through decree 307, dated November 27, 2012. The new conglomerate of 38 companies also includes entities within the Quimefa group and it was conceived following the technical and scientific level achieved by the country.

The decision to set up BioCubaFarma is in tune with the economic and social guidelines approved by the 6th Congress of the Cuban Communist Party about the consolidation of the pharmaceutical and biotechnological industry as one of the country’s areas with higher export capacity, and able to introduce new products into the local market to replace imports.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Biotechnology